EHMT2 and diffuse large B-cell lymphoma: In our current study, niclosamide treatment of four DLBCL cell lines (U2932, HT, SU-DHL-5, and RC-K8) reduced cell proliferation/viability and G9a expression in a dose-dependent manner (Figure 2 and Figure 3).